This study will test an investigational study drug called patritumab. It is a 'randomized
study' which means participants have an equal chance of being assigned to receive the
experimental medication (patritumab) or a substance that looks like the experimental product,
but is not (placebo). Patritumab may work when combined with other medications that are
approved for the treatment of head and neck cancer. They are called cetuximab, cisplatin or
carboplatin. All participants will receive the other medications approved for treatment of
head and neck cancer, even if they do not receive the experimental product.